This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignees: The University of Tokyo, Modalis Therapeutics Corporation. Active years: 2022-2024.
Location History:
- Bunkyo-ku, JP (2022)
- Tokyo, JP (2022 - 2023)
Company Filing History:
4 out of 1,355 
2 out of 6 Years Active: 2022-2024
Title: Hisato Hirano: Innovator in Gene Editing Technologies
Introduction
Hisato Hirano is a prominent inventor based in Bunkyo-ku, Japan. He has made significant contributions to the field of gene editing, particularly through his work on modified Cas9 proteins. With a total of four patents to his name, Hirano's innovations are paving the way for advancements in genetic research and applications.
Latest Patents
Hirano's latest patents include a modified Cas9 protein that exhibits a relaxed restriction on target sequences while maintaining its binding ability to guide RNA. This mutant SaCas9 protein features several specific amino acid mutations, which enhance its utility as a tool for gene editing. Another notable patent focuses on a polynucleotide encoding a modified Cas9 protein, which similarly aims to provide a more versatile gene editing tool.
Career Highlights
Throughout his career, Hirano has worked with esteemed institutions, including the University of Tokyo and Modalis Therapeutics Corporation. His research has significantly impacted the field of genetic engineering, particularly in developing more efficient gene editing techniques.
Collaborations
Hirano has collaborated with notable scientists such as Osamu Nureki and Hiroshi Nishimasu. These partnerships have further enriched his research and contributed to the advancement of gene editing technologies.
Conclusion
Hisato Hirano's innovative work in gene editing exemplifies the potential of modified Cas9 proteins in advancing genetic research. His contributions continue to influence the field and inspire future innovations.